Axim Biotechnologies Inc 's ROA from the second quarter of 2024 to the second quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Axim Biotechnologies Inc 's ROA in the second quarter of 2024?
Axim Biotechnologies Inc recorded a cumulative net loss of $-4 million during 12 months ending in the second quarter of 2024, resulting in a negative return on assets (ROA) of -104.52%.

However, within the Healthcare sector 850 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2024 quarter, so far to 4672, from total ROA ranking in the first quarter of 2024 at 4851.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter
Y / Y Total Assets Change	-12.21 %	-2.68 %	-2.15 %	-7.17 %	-0.92 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-4	-6	-8	-7	-9
Return On Assets (TTM)	-104.52 %	-136.77 %	-195.92 %	-162.66 %	-223.51 %
AXIM's Total Ranking	# 4672	# 4851	# 5713	# 5111	# 5306
Total Assets (TTM) in million	4	4	4	4	4
Seq. Total Assets Change	-5.26 %	-4.53 %	1.92 %	-4.77 %	5.03 %
Seq. Net Income Change	-	-	-	-	-

AXIM's 5 Years Annual ROA >> Back to AXIM Management Effectiveness >> Compare AXIM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 403
Sector	# 851
Overall	# 4590

Return On Assets Statistics
High	Average	Low
20763.21 %	940.57 %	-1216.91 %
(Jun 30 2014)		(Sep 30 2016)

Financial Statements
Axim Biotechnologies Inc 's Assets	$ 4 million	AXIM's Balance sheet
Axim Biotechnologies Inc 's Income	$ -2 million	Quarterly AXIM's Income Statement
AXIM's Income by Division		See AXIM's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019
Y / Y Total Assets Change	-2.15 %	-20.88 %	-52.95 %	568.73 %	-19.02 %
Total Assets in million	4	4	5	11	2
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-8	-6	-16	-6	-6
Annual Return On Assets	-195.55 %	-148.22 %	-301.16 %	-56.65 %	-381.08 %

AXIM's 5 Years Annual ROA >> Back to AXIM Management Effectiveness >> Compare AXIM ROA to its Competitors

More Return On Assets Ratios
AXIM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AXIM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AXIM's Competitors
Subscribers only: Roa for Axim Biotechnologies Inc 's Suppliers
Subscribers only: Return On Assets for AXIM's Customers

You may also want to know
AXIM's Roi	AXIM's Inventory Turnover Ratio	AXIM's Growth Rates	AXIM's Dividend Comparisons
	AXIM's Profitability Ratios	AXIM's Asset Turnover Ratio	AXIM's Dividend Growth
AXIM's Roe	AXIM's Valuation Ratios	AXIM's Financial Strength Ratios	AXIM's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.